Keywords: Multiple sclerosis, Patient share, Europe, Novartis, Gilenya, Decision Resources, Sanofi, Aubagio, Biogen Idec, BG-12
Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related
Article | 09 December 2012
Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod) has captured 5.4% of those multiple sclerosis (MS) patients treated with disease-modifying ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
